BioSystems International Initiates Development of a Diagnostic Blood Test for Lung Cancer

PARIS--(BUSINESS WIRE)--Biosystems International a biotechnology company focused on the development of novel monoclonal antibody-based cancer diagnostics has initiated the development of an in vitro diagnostic blood test for lung cancer. This decision is based on the successful validation of a panel of monoclonal antibodies on multiple cohorts of lung cancer patients and control subjects.
MORE ON THIS TOPIC